Eli Lilly reported strong Q2 results with robust revenue growth led by key drugs Mounjaro and Zepbound. The company raised its 2026 revenue guidance to $85–87 billion, supported by volume gains despite price declines, and expects continued margin expansion. A major catalyst is the upcoming Retatrutide drug, with a Biologics License Application planned for early 2027 and potential applications in new therapeutic areas. The stock is considered attractively valued with a potential 23.7% upside as Eli Lilly continues to outperform its sector.
Eli Lilly reported a historic 48% revenue growth in Q2 2026, driven by strong sales of Mounjaro and raised its full-year EPS guidance. Despite these results, the stock trades below its 52-week high due to concerns over U.S. price declines and acquisi...
Employer coverage for GLP-1 weight-loss drugs is declining, with many dropping these benefits by 2027. However, the FDA recently expanded the label for Eli Lilly's Mounjaro to include cardiovascular risk reduction in type 2 diabetes patients, strengt...
Eli Lilly and Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, Lilly's executive vice president and president of Lilly USA and Global Customer Capabilities, will join a firesid...
OpenAI has developed an AI-designed chip called Jalapeno that early tests show outperforms Nvidia's best chip, Blackwell, in total cost of ownership. While Nvidia currently benefits from scarcity in the market, a macro investor predicts this advantag...
Eli Lilly announced it will buy Merida Biosciences for up to $2.88 billion in cash to expand its treatments for immune-related and allergic diseases. Merida's lead drug candidate targets autoimmune disorders like Graves' disease and thyroid eye disea...
